期刊： MOLECULAR THERAPY, 2022; 30 (1)
Compact CRISPR-Cas9 systems that can be packaged into an adeno-associated virus (AAV) show promise for gene therapy. However, the requirement of proto......
期刊： MOLECULAR THERAPY, 2022; 30 (1)
Cas12a is an RNA-guided endonuclease that has been widely used for convenient multiplex gene editing with low off-target effects. To minimize off-targ......
期刊： MOLECULAR THERAPY, 2022; 30 (1)
The protein-coding ability of circular RNAs (circRNAs) has recently been a hot topic, but the expression and roles of protein-coding circRNAs in tripl......
期刊： MOLECULAR THERAPY, 2022; 30 (2)
Macrophages constitute a major component in human hepatocellular carcinoma (HCC) and perform various functions to facilitate disease progression. Repr......
期刊： MOLECULAR THERAPY, 2022; 30 (5)
Zitra virus (ZIKV), a flavivirus associated with neurological disorders, constitutes a global health threat. During pregnancy, ZIKV traverses the plac......
期刊： MOLECULAR THERAPY, 2022; 30 (6)
Amino acids metabolism, especially aspartate metabolism, is often altered in human cancers including hepatocellular carcinoma (HCC) and this metabolic......
期刊： MOLECULAR THERAPY, 2022; 30 (8)
The inefficient tumor penetration of therapeutic antibodies has hampered their effective use in treating solid tumors. Here, we report the identificat......
期刊： MOLECULAR THERAPY, 2022; 30 (8)
Translational reprogramming is part of the unfolded protein response (UPR) during endoplasmic reticulum (ER) stress, which acts to the advantage of ca......
期刊： MOLECULAR THERAPY, 2022; 30 (1)
Exercise training benefits the heart. The knowledge of posttranscription regulation, especially RNA editing, in hearts remain rare. ADAR2 is an enzyme......
期刊： MOLECULAR THERAPY, 2022; 30 (1)
Transthyretin (TTR) amyloidosis is a hereditary life -threatening disease characterized by deposition of amyloid fibrils. The main causes of TTR amylo......
期刊： MOLECULAR THERAPY, 2022; 30 (4)
Hepatoblastoma is the most common liver cancer in children, and the aggressive subtype often has a poor prognosis and lacks effective targeted therapy......
期刊： MOLECULAR THERAPY, 2022; 30 (12)
Activation of hepatic stellate cells (HSCs) is a central driver of liver fibrosis. Previous investigations have identified various altered epigenetic ......
期刊： MOLECULAR THERAPY, 2022; 30 (4)
N6-methyladenosine (m(6)A) methylation, which is modified by the METTL3/METTL14 complex, is a dominant internal modification in mammalian RNA and tigh......
期刊： MOLECULAR THERAPY, 2022; 30 (11)
Targeted therapy for lung squamous cell carcinoma (LUSC) re-mains a challenge due to the lack of robust targets. Here, we identified MECOM as a candid......
